Lyogenesis Holdings

LyGenesis is a clinical-stage biotechnology company developing a novel cell therapy platform that uses patients' lymph nodes as bioreactors to grow functioning ectopic organs. Their therapies target unmet needs in diseases such as end-stage liver disease, Type 1 diabetes, end-stage renal disease, and aging. This approach aims to revolutionize treatment by creating a less invasive and more economical alternative to traditional organ transplantation.